Here, we evaluated the impact of expressing a range of HLA‐I‐restricted tumour‐specific TCRs with different affinities for cognate antigen on CD4+ T cells and compared the functional efficacy of these redirected CD4+ T cells with CD8+ T cells expressing the same TCRs. The gene discussed is CD4; the disease is neoplasm.